A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
← catalyst calendarSponsored by ALX Oncology Inc. (industry) · ALXO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
36actual
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-02 | actual | When the study began enrolling |
| Primary completion | 2025-06-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-27 | actual | The whole study's end, after follow-up |
| First posted | 2022-09-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Bladder Cancer
- Urothelial Carcinoma
Interventions
- Drug: Evorpacept — also filed as ALX148
- Drug: Enfortumab Vedotin — also filed as PADCEV
Primary outcomes
what the primary-completion date above is the date OFFirst Cycle Dose limiting toxicities (DLTs)
measured Up to 28 days
Adverse Events (AEs) as characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v. 5.0)), timing, seriousness, and relationship to study therapy
measured Up to 24 months
Phase 1: Recommended Phase 2 Dose (RP2D)
measured Up to 15 months
Permalink · ALXO's whole pipeline · Catalyst calendar · Every registered study · What changed